Maxim Group Lowers IceCure Medical (NASDAQ:ICCM) Price Target to $1.00

IceCure Medical (NASDAQ:ICCM) had its target price cut by equities researchers at Maxim Group from $3.00 to $1.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s target price points to a potential upside of 335.16% from the company’s current price.

A number of other research firms have also commented on ICCM. Alliance Global Partners started coverage on IceCure Medical in a report on Monday, May 4th. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research note on Tuesday, April 21st. Finally, Wall Street Zen raised IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $2.09.

IceCure Medical Stock Performance

ICCM stock opened at $0.23 on Thursday. The stock’s 50 day simple moving average is $0.41 and its 200 day simple moving average is $0.57. IceCure Medical has a fifty-two week low of $0.22 and a fifty-two week high of $1.40. The company has a market cap of $18.67 million, a P/E ratio of -0.96 and a beta of 0.47.

IceCure Medical (NASDAQ:ICCM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.03). The company had revenue of $0.91 million during the quarter, compared to analysts’ expectations of $1.34 million. IceCure Medical had a negative return on equity of 211.73% and a negative net margin of 441.60%. Equities analysts predict that IceCure Medical will post -0.15 earnings per share for the current year.

Hedge Funds Weigh In On IceCure Medical

A number of institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new stake in IceCure Medical in the 4th quarter worth $39,000. Concurrent Investment Advisors LLC purchased a new position in IceCure Medical during the fourth quarter valued at approximately $48,000. Finally, Jane Street Group LLC purchased a new position in IceCure Medical in the fourth quarter worth $67,000. 0.62% of the stock is owned by institutional investors.

IceCure Medical News Roundup

Here are the key news stories impacting IceCure Medical this week:

• Positive Sentiment: Maxim Group still has a buy rating on IceCure Medical, even after cutting its price target to $1.00, suggesting upside from the current share price remains in the firm’s view.
• Neutral Sentiment: Nasdaq granted IceCure a 180-day extension, until November 9, 2026, to regain compliance with the minimum bid price requirement, avoiding an immediate listing problem but leaving the company under a watchful eye.
• Negative Sentiment: Brookline Capital Markets lowered its earnings estimates across multiple periods, including Q2 2026, FY2026, FY2027, FY2028, and FY2029, pointing to a slower path to profitability and weaker near-term expectations.
• Negative Sentiment: The company continues to face very low share price levels near its 52-week low, which amplifies investor concern around dilution, liquidity, and the risk of further volatility.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.